Sutro Biopharma Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Sutro Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $47.23. The average 1-year stock price forecast is 111.98% higher than the current stock price, while the lowest is $10 (-55.12%) and the highest is $61 (+173.79%).

Price Target: $47.23 (+111.98%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$10	$47.23	$50	$61
Change	-55.12%	+111.98%	+124.42%	+173.79%

Analyst Ratings

The average analyst rating for Sutro Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	6	8	9	9	9	10
Buy	2	2	3	3	3	3
Hold	1	1	0	0	0	0
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	10	12	13	13	13	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $48	Buy	Maintains	$48	+115.44%	Aug 17, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Sell Maintains n/a	Sell	Maintains	n/a	n/a	Aug 14, 2026
Tara Bancroft TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 13, 2026
Supawat Thongthip Truist Financial	Truist Financial	Buy Reiterates $50	Buy	Reiterates	$50	+124.42%	Aug 13, 2026
Eva Fortea Verdejo Wells Fargo	Wells Fargo	Buy Reiterates $49	Buy	Reiterates	$49	+119.93%	Aug 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

51.07M

from 102.48M

-50.17%

from 102.48M

Revenue Next Year

32.36M

from 51.07M

-36.63%

from 51.07M

EPS This Year

-7.77

from -16.20

EPS Next Year

-6.72

from -7.77

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	61.88M	67.77M	153.73M	62.04M	102.48M	51.07M
Revenue Growth	44.84%	9.52%	126.84%	-59.64%	65.18%	-50.17%
Operating Income	-98.52M	-128.94M	-89.28M	-238.45M	-104.95M	-114.38M
Net Income	-105.54M	-119.20M	-106.79M	-227.46M	-191.09M	-129.66M
EPS	-	-	-	-	-16.20	-7.77
Free Cash Flow	-59.62M	-41.16M	-36.57M	-78.99M	-112.39M	-100.77M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	124.4M
Avg	51.1M
Low	29.4M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	21.4%
Avg	-50.2%
Low	-71.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-6.39
Avg	-7.77
Low	-10.32

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-